DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Forteo (Teriparatide) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Treatment of Osteoporosis in Men and Postmenopausal Women

The safety of FORTEO in the treatment of osteoporosis in men and postmenopausal women was assessed in two randomized, double-blind, placebo-controlled trials of 1382 patients (21% men, 79% women) aged 28 to 86 years (mean 67 years). The median durations of the trials were 11 months for men and 19 months for women, with 691 patients exposed to FORTEO and 691 patients to placebo. All patients received 1000 mg of calcium plus at least 400 IU of vitamin D supplementation per day.

The incidence of all cause mortality was 1% in the FORTEO group and 1% in the placebo group. The incidence of serious adverse events was 16% in FORTEO patients and 19% in placebo patients. Early discontinuation due to adverse events occurred in 7% of FORTEO patients and 6% of placebo patients.

Table 1 lists adverse events from the two principal osteoporosis trials in men and postmenopausal women that occurred in ≥2% of FORTEO-treated and more frequently than placebo-treated patients.

Table 1. Percentage of Patients with Adverse Events Reported by at Least 2% of FORTEO-Treated Patients and in More FORTEO-Treated Patients than Placebo-Treated Patients from the Two Principal Osteoporosis Trials in Women and MenAdverse Events are Shown Without Attribution of Causality
FORTEO
N=691
Placebo
N=691
  Event Classification (%) (%)
  Body as a Whole
  Pain 21.3 20.5
  Headache 7.5 7.4
  Asthenia 8.7 6.8
  Neck pain 3.0 2.7
  Cardiovascular
  Hypertension 7.1 6.8
  Angina pectoris 2.5 1.6
  Syncope 2.6 1.4
  Digestive System
  Nausea 8.5 6.7
  Constipation 5.4 4.5
  Diarrhea 5.1 4.6
  Dyspepsia 5.2 4.1
  Vomiting 3.0 2.3
  Gastrointestinal disorder 2.3 2.0
  Tooth disorder 2.0 1.3
  Musculoskeletal
  Arthralgia 10.1 8.4
  Leg cramps 2.6 1.3
  Nervous System
  Dizziness 8.0 5.4
  Depression 4.1 2.7
  Insomnia 4.3 3.6
  Vertigo 3.8 2.7
  Respiratory System
  Rhinitis 9.6 8.8
  Cough increased 6.4 5.5
  Pharyngitis 5.5 4.8
  Dyspnea 3.6 2.6
  Pneumonia 3.9 3.3
  Skin and Appendages
  Rash 4.9 4.5
  Sweating 2.2 1.7

Immunogenicity — In the clinical trial, antibodies that cross-reacted with teriparatide were detected in 3% of women (15/541) receiving FORTEO. Generally, antibodies were first detected following 12 months of treatment and diminished after withdrawal of therapy. There was no evidence of hypersensitivity reactions or allergic reactions among these patients. Antibody formation did not appear to have effects on serum calcium, or on bone mineral density (BMD) response.

Laboratory Findings

Serum Calcium — FORTEO transiently increased serum calcium, with the maximal effect observed at approximately 4 to 6 hours post-dose. Serum calcium measured at least 16 hours post-dose was not different from pretreatment levels. In clinical trials, the frequency of at least 1 episode of transient hypercalcemia in the 4 to 6 hours after FORTEO administration was increased from 2% of women and none of the men treated with placebo to 11% of women and 6% of men treated with FORTEO. The number of patients treated with FORTEO whose transient hypercalcemia was verified on consecutive measurements was 3% of women and 1% of men.

Urinary Calcium — FORTEO increased urinary calcium excretion, but the frequency of hypercalciuria in clinical trials was similar for patients treated with FORTEO and placebo [see Clinical Pharmacology ].

Serum Uric Acid — FORTEO increased serum uric acid concentrations. In clinical trials, 3% of FORTEO patients had serum uric acid concentrations above the upper limit of normal compared with 1% of placebo patients. However, the hyperuricemia did not result in an increase in gout, arthralgia, or urolithiasis.

Renal Function — No clinically important adverse renal effects were observed in clinical studies. Assessments included creatinine clearance; measurements of blood urea nitrogen (BUN), creatinine, and electrolytes in serum; urine specific gravity and pH; and examination of urine sediment.

Studies in Men and Women with Glucocorticoid-Induced Osteoporosis

The safety of FORTEO in the treatment of men and women with glucocorticoid-induced osteoporosis was assessed in a randomized, double-blind, active-controlled trial of 428 patients (19% men, 81% women) aged 22 to 89 years (mean 57 years) treated with ≥ 5mg per day prednisone or equivalent for a minimum of 3 months. The duration of the trial was 18 months with 214 patients exposed to FORTEO and 214 patients exposed to oral daily bisphosphonate (active control). All patients received 1000 mg of calcium plus 800 IU of vitamin D supplementation per day.

The incidence of all cause mortality was 4% in the FORTEO group and 6% in the active control group. The incidence of serious adverse events was 21% in FORTEO patients and 18% in active control patients, and included pneumonia (3% FORTEO, 1% active control). Early discontinuation because of adverse events occurred in 15% of FORTEO patients and 12% of active control patients, and included dizziness (2% FORTEO, 0% active control).

Adverse events reported at a higher incidence in the FORTEO group and with at least a 2% difference in FORTEO-treated patients compared with active control-treated patients were: nausea (14%, 7%), gastritis (7%, 3%), pneumonia (6%, 3%), dyspnea (6%, 3%), insomnia (5%, 1%), anxiety (4%, 1%), and herpes zoster (3%, 1%), respectively.

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of FORTEO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Osteosarcoma: Cases of bone tumor and osteosarcoma have been reported rarely in the postmarketing period. The causality to FORTEO use is unclear. Long term osteosarcoma surveillance studies are ongoing [see Warnings and Precautions]
  • Hypercalcemia: Hypercalcemia greater than 13.0 mg/dL has been reported with FORTEO use.

Adverse events reported since market introduction that were temporally (but not necessarily causally) related to FORTEO therapy include the following:

  • Allergic Reactions: Anaphylactic reactions, drug hypersensitivity, angioedema, urticaria
  • Investigations: Hyperuricemia
  • Respiratory System: Acute dyspnea, chest pain
  • Musculoskeletal: Muscle spasms of the leg or back
  • Other: Injection site reactions including injection site pain, swelling and bruising; oro-facial edema


REPORTS OF SUSPECTED FORTEO SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Forteo. The information is not vetted and should not be considered as verified clinical evidence.

Possible Forteo side effects / adverse reactions in 73 year old female

Reported by a consumer/non-health professional from Germany on 2011-10-03

Patient: 73 year old female

Reactions: Dyspnoea, Listless, Nausea, Bone Pain, Arrhythmia, Myalgia, Sleep Disorder, Arthralgia, Heart Rate Increased, Dizziness, Depression, Asthenia, Heart Rate Abnormal, Muscle Spasms

Suspect drug(s):
Forteo

Other drugs received by patient: Vitamin D; Diclofenac Sodium; Calcium Carbonate



Possible Forteo side effects / adverse reactions in 73 year old female

Reported by a consumer/non-health professional from Germany on 2011-10-03

Patient: 73 year old female

Reactions: Femoral Neck Fracture, Fall

Adverse event resulted in: hospitalization

Suspect drug(s):
Forteo
    Dosage: unk, qd
    Start date: 2011-06-01
    End date: 2011-08-01

Forteo
    Dosage: unk, qd
    Indication: Osteoporosis
    Start date: 2010-06-21
    End date: 2011-04-01

Other drugs received by patient: Magnesium; Iron; Calcium +vit D



Possible Forteo side effects / adverse reactions in 79 year old female

Reported by a consumer/non-health professional from Japan on 2011-10-03

Patient: 79 year old female

Reactions: Nasopharyngitis, Lung Disorder

Suspect drug(s):
Forteo



See index of all Forteo side effect reports >>

Drug label data at the top of this Page last updated: 2013-10-16

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017